Edition:
United Kingdom

Allogene Therapeutics Inc (ALLO.OQ)

ALLO.OQ on NASDAQ Stock Exchange Global Select Market

29.12USD
21 May 2019
Change (% chg)

-- (--)
Prev Close
$29.12
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
119,444
52-wk High
$35.55
52-wk Low
$21.67

Revenue & Earnings Per Share

    Revenue* Earnings Per Share**
FY 2019 Mar '19 0.00 -0.325
FY 2018 Dec '18 0.00 -0.251
Sep '18 0.00 -0.377
Jun '18 0.00 -1.193
Mar '18 0.00 -0.099
 
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars

Consensus Estimates Analysis

  # of Estimates Mean High Low 1 Year Ago
SALES (in millions)
Quarter Ending Jun-19 7 0.00 0.00 0.00 --
Quarter Ending Sep-19 7 0.00 0.00 0.00 --
Year Ending Dec-19 8 0.00 0.00 0.00 --
Year Ending Dec-20 8 0.00 0.00 0.00 --
Earnings (per share)
Quarter Ending Jun-19 7 -0.46 -0.42 -0.52 --
Quarter Ending Sep-19 7 -0.54 -0.50 -0.59 --
Year Ending Dec-19 7 -1.99 -1.89 -2.05 --
Year Ending Dec-20 8 -2.59 -2.08 -2.93 --
Sales and Profit Figures in US Dollar (USD);

Valuation Ratios

  Company industry sector
P/E Ratio (TTM) -- 69.30 32.55
P/E High - Last 5 Yrs. -- 147.69 48.12
P/E Low - Last 5 Yrs. -- 47.94 23.41
Beta -- 1.08 0.87
Price to Sales (TTM) -- 49.50 8.44
Price to Book (MRQ) -- 10.13 5.27
Price to Tangible Book (MRQ) -- 13.74 6.74
Price to Cash Flow (TTM) -- 56.16 24.12
% Owned Institutions -- 3.71 1.65

Dividends

  Company industry sector
Dividend Yield -- 0.12 1.35
Dividend Yield - 5 Year Avg -- 0.09 1.37
Dividend 5 Year Growth Rate -- 0.78 4.70
Payout Ratio(TTM) -- 7.02 39.61

Growth Rates

  Company industry sector
Sales (MRQ) vs Qtr. 1 Yr. Ago -- 206.05 13.46
Sales (TTM) vs TTM 1 Yr. Ago -- 49.05 8.04
Sales - 5 Yr. Growth Rate -- 22.77 10.84
EPS (MRQ) vs Qtr. 1 Yr. Ago -- 75.33 47.72
EPS (TTM) vs TTM 1 Yr. Ago -- -- --
EPS - 5 Yr. Growth Rate -- 11.97 10.46
Capital Spending - 5 Yr. Growth Rate -- 9.11 14.68

Financial Strength

  Company industry sector
Quick Ratio (MRQ) -- 2.24 2.18
Current Ratio (MRQ) -- 3.57 2.98
LT Debt to Equity (MRQ) -- 18.62 11.32
Total Debt to Equity (MRQ) -- 31.29 16.01
Interest Coverage (TTM) -- -43.11 28.46

Profitability Ratios

  Company industry sector
Gross Margin (TTM) -- 56.27 52.40
Gross Margin - 5 Yr. Avg. -- 60.50 50.39
EBITD Margin (TTM) -- -- --
EBITD - 5 Yr. Avg -- -110.81 12.41
Operating Margin (TTM) -- -184.81 5.67
Operating Margin - 5 Yr. Avg. -- -127.30 8.00
Pre-Tax Margin (TTM) -- -175.49 4.69
Pre-Tax Margin - 5 Yr. Avg. -- -133.09 8.28
Net Profit Margin (TTM) -- -182.21 1.42
Net Profit Margin - 5 Yr. Avg. -- -137.48 4.69
Effective Tax Rate (TTM) -- 22.46 22.13
Effective Tax Rate - 5 Yr. Avg. -- 15.50 22.58

Efficiency

  Company industry sector
Revenue/Employee (TTM) -- 7,653,038 820,086,371
Net Income/Employee (TTM) -- 513,433 92,829,218
Receivable Turnover (TTM) -- 6.28 5.82
Inventory Turnover (TTM) -- 1.89 3.41
Asset Turnover (TTM) -- 0.32 0.90

Management Effectiveness

  Company industry sector
Return on Assets (TTM) -- 6.38 10.65
Return on Assets - 5 Yr. Avg. -- 5.47 11.78
Return on Investment (TTM) -- 8.91 13.82
Return on Investment - 5 Yr. Avg. -- 6.78 15.32
Return on Equity (TTM) -- 10.05 15.24
Return on Equity - 5 Yr. Avg. -- 8.36 16.41

Performance for Allogene Therapeutics Inc

Period %
Actual
% vs.
S&P 500
Rank In
Industry
Industry
Rank
4 Week -- -- -- 99
13 Week -- -- -- 95
26 Week -- -- -- 97
52 Week -- -- -- 69
YTD -- -- -- 72
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.

Institutional Holders

% Shares Owned: 52.64%
# of Holders: 127
Total Shares Held: 63,976,981
3 Mo. Net Change: 876,266
# New Positions: 26
# Closed Positions: 14
# Increased Positions: 69
# Reduced Positions: 40
# Net Buyers: 29
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.